Arkansas Urology — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$13,232	4
2024	Research	$297,981	5
2023	Research	$28,510	5
2022	Research	$20,510	3
2021	Research	$35,685	8
2020	Research	$61,048	8
2019	Research	$45,549	7

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $286,677 5 payments
Dendreon Pharmaceuticals LLC $196,615 29 payments
Ironwood Pharmaceuticals, Inc $17,242 4 payments
Pfizer Inc. $1,982 2 payments

Studies the money was for Research payments · program years 2019–2025

a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco $272,243 1 payment
A Randomized Phase 3, Open-Label Trial of Sipuleucel-T Administered to Patients on Active Surveillance for Newly Diagnosed Prostate Cancer $92,518 15 payments
Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer (Provent) $61,048 8 payments
Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer Provent $43,049 6 payments
C3300-201 $17,242 4 payments
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib Abiraterone Versus Placebo Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281) $10,434 2 payments
A Non-Interventional Primary Data Collection Study to Assess the Prevalence of PD-L1 High in First Line Metastatic and Locally Advanced Urothelial Carcinoma Study (mUC) $4,000 2 payments
A Phase 3 Randomized Double Blind Placebo Controlled Study of Pf06821497 Mevrometostat With Enzalutamide in Metastatic Castration Resistant Prostate Cancer Mevpro2 $1,982 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.